<DOC>
	<DOCNO>NCT00113256</DOCNO>
	<brief_summary>Patients treat gemcitabine Orathecin ( rubitecan ) capsule evaluate current estimate overall survival study endpoint prior launch blind randomized phase ( versus gemcitabine placebo ) study . Toxicity drug combination also evaluate .</brief_summary>
	<brief_title>Orathecin + Gemcitabine Versus Placebo + Gemcitabine Chemonaive Non-Resectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Rubitecan</mesh_term>
	<criteria>The patient least 18 year age . The patient histologically cytologically confirm , nonresectable , Stage IIIV primary adenocarcinoma pancreas . The patient baseline compute tomography ( CT ) scan , magnetic resonance imaging ( MRI ) , evaluate tumor ( ) within 28 day prior randomization . The patient never treat prior chemotherapy , exception lowdose 5fluorouracil ( 5FU ) radiation sensitizer . The patient sufficiently recover effect previous surgery ( le 3 week prior randomization ) , radiotherapy , and/or immunotherapy ( le 4 week prior randomization ) . The patient 's estimate life expectancy least 12 week . The patient Karnofsky Performance Status 50 100 . The patient adequate bone marrow function . The patient adequate hepatic renal function . The patient active , uncontrolled infection require antibiotic . The patient serious , uncontrolled concomitant systemic disorder . The patient surgery schedule within 8 week follow initiation treatment . The patient pregnant nursing . The patient capable consistent oral intake least 3 L/day fluid and/or require constant intravenous ( IV ) hydration frequent tube feeding . The patient receive investigational agent ( ) participant clinical trial within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>rubitecan</keyword>
	<keyword>Orathecin</keyword>
	<keyword>9-nitrocamptothecin</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>Gemzar</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>RFS 2000</keyword>
</DOC>